Evolugate Takes Up the Challenge of Boosting Host Cells Used to Manufacture COVID-19 Vaccines (The Science Advisory Board)

Evolugate Takes Up the Challenge of Boosting Host Cells Used to Manufacture COVID-19 Vaccines

The COVID-19 epidemic has left the world devastated, with over 350,000 dead and the global economy in shambles in just 5 months. A vaccine for the virus that causes COVID-19, SARS-CoV-2, is desperately needed, yet vaccine development typically takes years from conception to deployment. Developing a safe and effective vaccine is an important first step, but just as critical is the problem of how to quickly manufacture the billions of doses of vaccine the world needs. While it is important not to skip the early steps of development for the sake of safety and efficacy, the time it will take to increase production from a few doses to the billions necessary will be measured in lives, social disruption and economic damage.

UF startup Evolugate, LLC, a leading technology provider in the evolutionary optimization of micro-organisms used in the various fields of biopesticides, green chemistry, probiotics, agronomy, bioremediation, as well as in the pharmaceutical industry for bio-production, has proprietary technology for improving industrial microorganisms and extensive experience in the field of industrial fermentation that can be used to increase the productivity of the cells that will be used to produce those COVID-19 vaccines that eventually win FDA approval. Evolugate will be able to help vaccine manufacturers reduce the time it takes to make each dose, shortening the time it will take to get the vaccines to market.

Learn more about Evolugate Takes Up the Challenge of Boosting Host Cells Used to Manufacture COVID-19 Vaccines.
X